177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

PurposeThere is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled...

Full description

Bibliographic Details
Main Authors:	Ting Bu, Lulu Zhang, Fei Yu, Xiaochen Yao, Wenyu Wu, Pengjun Zhang, Liang Shi, Shiming Zang, Qingle Meng, Yudan Ni, Guoqiang Shao, Xuefeng Qiu, Shuyue Ai, Ruipeng Jia, Hongqian Guo, Feng Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Series:	Frontiers in Oncology
Subjects:	177Lu prostate cancer metastatic castration-resistant prostate cancer (mCRPC) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.835956/full

Similar Items

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Sazan Rasul, et al.
Published: (2021-05-01)

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
by: Nicolai Mader, et al.
Published: (2023-09-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
by: Kim N. Chi, et al.
Published: (2024-03-01)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&T
by: Philipp E. Hartrampf, et al.
Published: (2022-01-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
by: Yuanzhuo Yan, et al.
Published: (2024-03-01)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
by: Andreas Rinscheid, et al.
Published: (2020-06-01)

Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
by: Mikhail Rumiantcev, et al.
Published: (2023-09-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
by: Majid Assadi, et al.
Published: (2022-12-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Robin Wrenger, et al.
Published: (2022-07-01)

Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
by: Felix Kind, et al.
Published: (2022-04-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
by: Thomas Langbein, et al.
Published: (2022-08-01)

Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
by: Felix Kind, et al.
Published: (2021-12-01)

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
by: Florian Rosar, et al.
Published: (2022-05-01)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
by: Julia Brosch-Lenz, et al.
Published: (2021-03-01)

Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives
by: Rahaf Alsadi, et al.
Published: (2022-07-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

Comparative Analysis of Morphological and Functional Effects of <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands
by: Benedikt Feuerecker, et al.
Published: (2023-11-01)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01)

Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-Dichloride
by: Justus Baumgarten, et al.
Published: (2022-01-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022-03-01)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
by: Sonia Mahajan, et al.
Published: (2022-07-01)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01)

Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
by: Sandra Resch, et al.
Published: (2023-02-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023-05-01)

PSMA-targeted therapy for non-prostate cancers
by: Jarey H. Wang, et al.
Published: (2023-08-01)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
by: Murali Kesavan, et al.
Published: (2021-03-01)

Response Assessment and Prediction of Progression-Free Survival by <sup>68</sup>Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Fadi Khreish, et al.
Published: (2021-07-01)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01)

Lutetium-177-PSMA-617: A Vision of the Future
by: Elias Chandran, et al.
Published: (2022-12-01)